Omeros Corporation News

Traders in Omeros Attributing Upside in Shares to Bullish Note from MLV & Co., Says Trend Higher 'Will Continue'

Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock

SEATTLE, May 14, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, ...

Investors are Digesting These Healthcare Stock Earnings Insights

Short Interest Jumps 41.2% For OMER

The most recent short interest data has been released by the NASDAQ for the 04/30/2013 settlement date, which shows a 1,529,276 share increase in total short interest for Omeros Corp , to 5,239,997, an increase of 41.21% since 04/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex

Omeros Corporation Reports First Quarter 2013 Financial Results

SEATTLE, May 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, ...

Omeros Announces 3.9M Share Direct Offering of Common Stock at $4.14/Share

Omeros Announces $16.2 Million Registered Direct Offering of Common Stock

SEATTLE, May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium ...

Omeros Earnings: Everything You Must Know Now

Omeros Corp. (OMER) Reports In-Line Q1 EPS

OMEROS CORP Files SEC form 10-Q, Quarterly Report

InPlay: Omeros requests Fast Track Designation for OMS824 for the treatment of Huntington's disease

Omeros requests fast track designation for OMS824

Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease

SEATTLE, May 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has requested Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development ...

Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review

SEATTLE, April 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the European Medicines Agency (EMA) has confirmed that the Company's planned Marketing Authorization Application ...